Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKI1A8
|
|||
| Drug Name |
ALXN2080
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Phase 1 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement factor D (CFD) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | Platelet degranulation | |||
| Alternative complement activation | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Human Complement System | ||||
| Adipogenesis | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05428696) A Randomized, Double-blind, Placebo-controlled First-in-Human Study of Single and Multiple Doses of ALXN2080 in Healthy Participants. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Alexion | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.